CINECA IRIS Institutional Research Information System

SIMIELE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.326
EU - Europa 4.873
AS - Asia 2.185
SA - Sud America 294
AF - Africa 78
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 13
Totale 15.800
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.244
DK - Danimarca 1.391
SG - Singapore 849
CN - Cina 806
IT - Italia 785
DE - Germania 503
IE - Irlanda 393
FR - Francia 353
SE - Svezia 319
FI - Finlandia 272
BR - Brasile 246
UA - Ucraina 182
GB - Regno Unito 159
AT - Austria 147
KR - Corea 134
PL - Polonia 123
IN - India 87
VN - Vietnam 77
NL - Olanda 70
JP - Giappone 54
CA - Canada 51
ID - Indonesia 47
BE - Belgio 42
ZA - Sudafrica 34
AU - Australia 29
ES - Italia 25
HK - Hong Kong 21
RU - Federazione Russa 21
MX - Messico 19
CZ - Repubblica Ceca 17
TH - Thailandia 17
CH - Svizzera 15
EG - Egitto 15
TW - Taiwan 15
RO - Romania 12
EU - Europa 11
TR - Turchia 11
BD - Bangladesh 10
GR - Grecia 10
CL - Cile 9
CO - Colombia 9
AR - Argentina 8
PE - Perù 8
SA - Arabia Saudita 8
HU - Ungheria 7
IQ - Iraq 7
PK - Pakistan 7
HR - Croazia 6
PH - Filippine 6
UZ - Uzbekistan 6
MA - Marocco 5
PY - Paraguay 5
SN - Senegal 5
BO - Bolivia 4
NO - Norvegia 4
AZ - Azerbaigian 3
BZ - Belize 3
EC - Ecuador 3
IL - Israele 3
JO - Giordania 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
TZ - Tanzania 3
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
ET - Etiopia 2
GH - Ghana 2
IR - Iran 2
JM - Giamaica 2
KE - Kenya 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BS - Bahamas 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
KW - Kuwait 1
LI - Liechtenstein 1
LT - Lituania 1
MD - Moldavia 1
ME - Montenegro 1
MT - Malta 1
MU - Mauritius 1
MW - Malawi 1
NA - Namibia 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
SC - Seychelles 1
SV - El Salvador 1
Totale 15.797
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.688
Chandler 656
Beijing 523
Singapore 480
Dublin 391
Santa Clara 362
Fairfield 333
Torino 300
Ashburn 287
Houston 269
Wilmington 239
Villeurbanne 228
Dearborn 200
Woodbridge 195
Seattle 162
Nyköping 148
Princeton 143
Jacksonville 132
Medford 129
Vienna 118
Redwood City 110
Cambridge 107
Warsaw 105
Columbus 93
Munich 88
Pisa 63
Fremont 60
New York 55
Milan 53
Nuremberg 53
Boston 46
Turin 45
Jakarta 44
Guangzhou 37
Boardman 36
Shanghai 34
Helsinki 30
San Diego 30
Dong Ket 26
Hefei 26
Nanjing 26
Brussels 25
Toronto 25
Turku 24
Paris 21
Verona 20
Norwalk 17
Amsterdam 16
Hong Kong 16
Los Angeles 16
Omaha 15
London 14
Phoenix 14
São Paulo 14
Kunming 13
Rome 13
Dallas 12
Nürnberg 12
Rio de Janeiro 12
Falls Church 11
Taipei 11
Brno 10
Jinan 10
Lodz 10
Minneapolis 10
Silver Spring 10
Washington 10
Zhengzhou 10
Cape Town 9
Chicago 9
Coimbatore 9
Cairo 8
Des Moines 8
Edinburgh 8
Falkenstein 8
Mexico City 8
Mumbai 8
Raritan 8
Recife 8
Buffalo 7
Chengdu 7
Genoa 7
Hangzhou 7
Mountain View 7
Tokyo 7
Brescia 6
Budapest 6
Chennai 6
Durban 6
Düsseldorf 6
Göteborg 6
Lima 6
Medellín 6
Nanchang 6
Nola 6
San Mateo 6
Stockholm 6
Ankara 5
Bangkok 5
Belo Horizonte 5
Totale 9.761
Salva come PNG Salva come JPEG
Nome #
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 436
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 419
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 376
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 338
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 329
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 306
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 300
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 296
Raltegravir penetration in seminal plasma of healthy volunteers. 266
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 266
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 257
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 253
Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. 246
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 240
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 210
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 203
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 199
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 199
Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes 198
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 192
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 186
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 186
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 184
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 184
Farmacocinetica dell’anidulafungina in pazienti con fibrosi cistica, trapianto epatico e emodiafiltrazione: dati preliminari. 181
Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. 180
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 178
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 174
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 173
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 172
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 172
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 172
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 172
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 171
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification 171
Cannabis FM2: optimization and standardization of galenic preparations. 171
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 168
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 167
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 166
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 166
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 164
TCH-042 Stability Study of Ganciclovir in 0.9% Sodium Chloride in Different Types of Containers: Optimization of Resources 164
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 164
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 164
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 163
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. 161
Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina 160
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 157
Sviluppo di protocolli operativi standard per l’ottimizzazione di preparazioni galeniche allestite con cannabis “FM2” 157
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 154
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 154
Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. 154
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 154
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 154
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 152
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 151
Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico. 151
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 150
How effective are the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring? 150
Prophylaxis drug monitoring of itraconazole and voriconazole in the paediatric onco-haematological setting 149
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 148
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 147
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 143
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 141
Cannabinoids concentration variability in cannabis olive oil galenic preparations 133
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 118
Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability 112
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 111
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 110
Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. 106
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 106
Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots 101
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 100
New UPLC-MS/MS method for simultaneous determination of dolutegravir, elvitegravir, rilpivirine and other 14 HIV drugs in human plasma 99
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 98
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 98
Efavirenz pharmacogenetics in a cohort of Italian patients 98
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 98
Class-specific relative genetic contribution for key antiretroviral drugs 95
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 94
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. 91
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP). 90
Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml 86
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 85
Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole 85
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 83
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens 82
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. 81
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma 80
Single nucleotide polymorphisms of ABCB1 gene influence on intracellular concentrations of dasatinib. 77
Determinants of Renal Tubular Dysfunction in HIV-positive Patients of More than 50 Years-old 76
Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms 76
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations 75
A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma 75
Impact of Different Procedures of Galenic Formulations of Cannabis on Cannabinoids Contents 73
Analytical validation of a novel UHPLC-MS/MS method for 19 antibiotics quantification in plasma: Implementation in a LC-MS/MS Kit 66
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. 66
QUALITATIVE AND QUANTITATIVE EVALUATION OF DIFFERENT PHARMACEUTICAL PRODUCTS CONTAINING QUETIAPINE: BRAND VERSUS GENERIC 66
Therapeutic Drug Monitoring of Boosted Protease Inhibitors and 48-week Risk of Virological Failure 65
Single Nucleotide Polymorphisms of ABCB1 Gene Influence Daptomycin Pharmacokinetics in Adult Patients. [A-1769] 62
Totale 15.946
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.652
article - articoli 0
book - libri 0
conference - conferenze 15.689
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.341
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.515 354 51 42 86 88 77 76 49 105 123 105 359
2021/20223.317 324 298 318 346 249 277 355 285 205 98 287 275
2022/20231.990 208 111 43 184 202 529 133 144 209 38 127 62
2023/2024817 77 140 45 50 65 136 26 60 5 31 70 112
2024/20252.216 16 98 109 180 605 169 48 161 202 128 159 341
2025/2026126 126 0 0 0 0 0 0 0 0 0 0 0
Totale 16.536